Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 4/2009

01-12-2009

Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer

Authors: Emma Edwards, Catharina Yearwood, Julie Sillibourne, Diana Baralle, Diana Eccles

Published in: Familial Cancer | Issue 4/2009

Login to get access

Abstract

De novo mutations are rarely reported in BRCA1 and BRCA2. We report a proven BRCA1 de novo mutation in a woman diagnosed with young onset bilateral breast cancer with a limited family history.
Literature
1.
McIntosh A, Shaw C, Evans G et al (2004) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care/University of Sheffield, London
2.
Newman B, Mu H, Butler LM et al (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279:915–921CrossRefPubMed
3.
Anton-Culver H, Cohen PF, Gildea ME et al (2000) Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 36:1200–1208CrossRefPubMed
4.
Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529–1531CrossRefPubMed
5.
Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308CrossRef
6.
Ellis D, Greenman J, Hodgson S et al (2000) Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history. J Med Genet 37:792–794CrossRefPubMed
7.
Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462PubMed
8.
Clementi M, Barbujani G, Turolla L et al (1990) Neurofibromatosis-1: a maximum likelihood estimation of mutation rate. Hum Genet 84:116–118CrossRefPubMed
9.
Upadhyaya M, Majounie E, Thompson P et al (2003) Three different pathological lesions in the NF1 gene originating de novo in a family with neurofibromatosis type 1. Hum Genet 112:12–17CrossRefPubMed
10.
Milewicz DM, Duvic M (1994) Severe neonatal Marfan syndrome resulting from a de novo 3-bp insertion into the fibrillin gene on chromosome 15. Am J Hum Genet 54:447–453PubMed
11.
Booms P, Withers AP, Boxer M et al (1997) A novel de novo mutation in exon 14 of the fibrillin-1 gene associated with delayed secretion of fibrillin in a patient with a mild Marfan phenotype. Hum Genet 100:195–200CrossRefPubMed
12.
Tesoriero A, Andersen C, Southey M et al (1999) De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 65:567–569CrossRefPubMed
13.
van der Luijt RB, van Zon PH, Jansen RP et al (2001) De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. J Med Genet 38:102–105CrossRefPubMed
14.
Robson M, Scheuer L, Nafa K et al (2002) Unique de novo mutation of BRCA2 in a woman with early onset breast cancer. J Med Genet 39:126–128CrossRefPubMed
15.
Evans DG, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41:474–480CrossRefPubMed
16.
Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158CrossRefPubMed
17.
Hopper JL, Chenevix-Trench G, Jolley DJ et al (1999) Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr 26:95–100
18.
Southey MC, Tesoriero AA, Andersen CR et al (1999) BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer 79:34–39CrossRefPubMed
19.
Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949CrossRefPubMed
20.
Malone KE, Daling JR, Thompson JD et al (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922–929CrossRefPubMed
21.
Malone KE, Daling JR, Neal C et al (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393–1402CrossRefPubMed
22.
Loman N, Johannsson O, Kristoffersson U et al (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93:1215–1223CrossRefPubMed
23.
de Sanjosé S, Leone M, Berez V et al (2003) Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 106:588–93
24.
Plaschke J, Commer T, Jacobi C et al (2000) BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease. J Med Genet 37:E17CrossRefPubMed
25.
Bonadona V, Sinilnikova OM, Chopin S et al (2005) Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer 43:404–413CrossRefPubMed
26.
Choi DH, Lee MH, Bale AE et al (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638–1645CrossRefPubMed
27.
Loizidou M, Marcou Y, Anastasiadou V et al (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 71:165–170CrossRefPubMed
28.
Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175–5180CrossRefPubMed
Metadata
Title
Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer
Authors
Emma Edwards
Catharina Yearwood
Julie Sillibourne
Diana Baralle
Diana Eccles
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9270-8

Other articles of this Issue 4/2009

Familial Cancer 4/2009 Go to the issue

OriginalPaper

Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease

OriginalPaper

Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay

OriginalPaper

Attitude towards pre-implantation genetic diagnosis for hereditary cancer

BriefCommunication

Molecular study of CEPBA in familial hematological malignancies

OriginalPaper

The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women

OriginalPaper

Association of MUTYH and MSH6 germline mutations in colorectal cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits